3 reasons Pfizer and BioNTech will have coronavirus vaccine data before Moderna

Different clinical trial designs gives the duo an advantage, but coming in first isn't the end goal for vaccine makers.

| More on:
person receiving coronavirus vaccine injection into the arm

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) started the phase 3 clinical trial for their coronavirus vaccine BNT162b2 around the same time as Moderna Inc (NASDAQ: MRNA) started its phase 3 study for mRNA-1273.

But all signs point to Pfizer and BioNTech generating faster efficacy data than Moderna. Here's why:

1. Faster coronavirus vaccine booster shot

Pfizer and BioNTech give the booster shot for their vaccine 21 days after the initial dose, while Moderna's protocol calls for doctors to wait 28 days before giving the second dose. Since the efficacy measurements don't start until after the second dose is administered, the difference produces a week advantage for Pfizer and BioNTech.

2. COVID-19 efficacy readout is quicker

The efficacy in both clinical trials is based on the rate of COVID-19 among participants who receive the vaccine compared to the participants who receive placebo. But Pfizer and BioNTech decided to measure the rate of infection after seven days, while Moderna doesn't start measuring efficacy until 14 days after the second dose.

The difference creates an additional seven-day advantage for Pfizer and BioNTech compared to Moderna. Of course it's only an advantage if patients are truly protected during that seven-day period. Presumably the decisions of seven days for Pfizer and BioNTech vs. 14 days for Moderna were based on when the companies saw the formation of antibodies in earlier studies, but Moderna's conservative approach could end up benefiting the company with a slower-but-more-accurate efficacy readout.

3. Quicker enrollment

Since the efficacy measurement is events driven, early enrollment of participants in the study should help the companies generate efficacy data quicker.

Pfizer and BioNTech appear to have the edge here too, with 28,146 participants having received two doses of their vaccine as of Oct. 5,  compared to 19,369 participants in Moderna's clinical trial as of the update a few days earlier on Oct. 2.

Potential bonus: Interim readouts

If BNT162b2 works really well, Pfizer and BioNTech could have a time advantage over Moderna based on how the companies have set up their clinical trials.

Both studies incorporate multiple interim evaluations of efficacy to determine whether the studies should be stopped early if it's clear the vaccine is working. Pfizer and BioNTech have interim looks after 32, 62, 92, and 120 participants have developed COVID-19. Moderna's study only incorporated interim looks after 53 and 106 cases of COVID-19.

While the protocols offer an opportunity for Pfizer and BioNTech to call their clinical trial a success after 32 events, well before Moderna can even take a look at its data at 53 events, investors should keep in mind that the extra peeks at the data come at a statistical cost.

As a result, if both studies go to the end of their analysis, Pfizer and BioNTech need the vaccine efficacy to be 52.3% at the final readout with at least 111 of the 164 positive patients in the group who received placebo. Because Moderna has fewer interim looks, the biotech company only needs a vaccine efficacy of 49.5%, or 101 of the 151 positive patients falling in the placebo group, to call the clinical trial a success.

Is "October" vs "Thanksgiving" all that important?

Pfizer and BioNTech have told investors that data could come as early as October, while Moderna's management has said data should be available around Thanksgiving. That's only a few weeks' difference, with the obvious caveats that neither group can really know the timeline given the unknown infection rate.

The first group with data will have an advantage if it can gain the Food and Drug Administration's attention after requesting an emergency use authorization (EUA). But in a pandemic, the FDA's workload isn't necessarily a first-in-first-out situation. Better efficacy by the second vaccine maker could even the playing field, or perhaps even give it an advantage in the timing of authorizations.

And investors should keep in mind that demand is likely to outstrip manufacturing capacity. While the timing of an EUA is important, if the authorizations come in similar time frames, the group with the ability to manufacture the most vaccine is likely to capture the largest market share.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Brian Orelli, PhD and the Motley Fool have no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on International Stock News

A graphic illustration with the words NASDAQ atop a US city and currency
International Stock News

Why Big Tech became a huge wreck across the Nasdaq last night

Jerome Powell and his compadres shocked the market with an unexpected outlook.

Read more »

a man sits at a bar leaning sadly on his basketball wearing a US flag sticker on his cheekbone near a half drunk beer and looking despondent as though his basketball team has just lost a game.
International Stock News

The Dow Jones is on its longest losing streak in 46 years. What's going on?

The Dow is on a losing streak in the middle of a boom.

Read more »

A person leans over to whisper a secret to a colleague during a meeting.
International Stock News

Despite recent news, analysts still say Nvidia stock is a buy. Here's why

Last month, Nvidia was the most valuable company in the world.

Read more »

A young girl looks up and balances a pencil on her nose, while thinking about a decision she has to make.
International Stock News

After gaining 2,100%, is Nvidia stock done?

Nvidia has taken off as one of the key players in chips and services for artificial intelligence.

Read more »

A young couple in the back of a convertible car each raise a single arm in the air whilst enjoying a drive along the road.
International Stock News

Why Tesla stock just jumped again

Wedbush's Dan Ives thinks the stock will keep moving higher thanks to Tesla's self-driving technology.

Read more »

An older couple hold hands as they bounce happily high in the air.
International Stock News

Why the Alphabet share price just leapt higher

Investors seem to hope the Trump administration will be friendly to Alphabet and its big-tech peers.

Read more »

A panel of four judges hold up cards all showing the perfect score of ten out of ten
International Stock News

Top Wall Street analyst calls Tesla stock a top pick. Is it a buy now?

Tesla shares have been on fire lately, rising more than 70% since the November 5 election.

Read more »

a couple clink champagne glasses on board a private aircraft with gourmet food plates set in front of them. They are wearing designer clothes and looking wealthy.
International Stock News

Billionaires love this US tech stock (Hint: It's not Nvidia)

Looking for the next big thing in tech investments? Several billionaire-owned hedge funds are heavily invested in one overlooked AI…

Read more »